fda approval: frontline ceritinib for alk nsclc
Published 7 years ago • 121 plays • Length 5:31Download video MP4
Download video MP3
Similar videos
-
0:55
dr. west on fda approval of frontline alectinib in alk nsclc
-
9:00
fda d.i.s.c.o.: two approvals for alk-positive non-small cell lung cancer
-
2:06
dr. alice t. shaw on ceritinib for frontline alk nsclc with brain metastases
-
1:21
fda approval of frontline osimertinib in frontline egfr-mutant nsclc
-
6:51
progression in alk nsclc after frontline therapy
-
1:22
dr. liu on navigating the frontline treatment of alk nsclc
-
3:04
management of frontline alk nsclc: brigatinib vs. alectinib
-
3:14
dr. west on fda approval of frontline osimertinib in egfr nsclc
-
1:42
dr. velcheti on potential of alectinib in frontline alk-positive nsclc
-
6:37
ascend-4: upfront ceritinib in alk-rearranged nsclc
-
0:40
copy of dr. west on fda approval of frontline osimertinib in egfr nsclc
-
1:27
dr. neal debates whether alectinib will become the standard frontline thera for alk nsclc
-
4:37
fda approval of brigatinib for alk nsclc
-
1:48
dr. chow on the use of ceritinib in alk nsclc metastatic to the brain
-
9:00
fda d.i.s.c.o.: two approvals for alk-positive non-small cell lung cancer
-
2:35
dr. west on fda approval of brigatinib in alk nsclc
-
7:13
alectinib for relapsed/refractory alk nsclc
-
2:43
dose escalation results of ceritinib and nivolumab for alk nsclc
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc